Medtronic's MiniMed Go technology was designed to deliver real-time health data and recommendations to patients with type 1 and type 2 diabetes. It works with the Instinct sensors designed by Abbott.

This product was distributed throughout the United States from April 2022 to December 2025. Customers have been warned to stop taking it immediately. 

The FTC argued that the $945M deal, first announced in 2024, was "anticompetitive." A federal judge agreed. 

Silintan is a dietary supplement marketed as a treatment for joint and body aches. According to a recent analysis by the FDA, however, all lots contained undeclared meloxicam, creating an increased risk of adverse events.

Financial literacy is no longer optional for physicians. “If you're not financially viable, you can't function,” explained Nirat Beohar, MD. “The business education is probably just as important as learning a new procedure.”

These patients are typically treated with surgery, but those procedures carry their own risks that clinicians would prefer to avoid.

The ACC and AHA have published updated performance and quality measures focused on the diagnosis and management of peripheral artery disease. Several other specialty societies, including SCAI and SIR, also participated in the development of this new document.

RSNA is looking for a replacement for Suhny Abbara, MD, who is now the editor-in-chief of its flagship journal.

A vulnerable heart patient required TAVR, but he faced an extremely high risk of coronary obstruction. Leaflet modification and snorkel stenting were not possible, so the group turned to a brand new treatment option: the VECTOR procedure.

Mirvat Alasnag, MD, spoke to Cardiovascular Business about CCTA's growing influence in cardiology.